Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.23
+0.08 (1.12%)
At close: May 22, 2026, 4:00 PM EDT
7.37
+0.14 (1.94%)
After-hours: May 22, 2026, 5:56 PM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $10.84M in the quarter ending March 31, 2026, with 37,272.41% growth. This brings the company's revenue in the last twelve months to $45.07M, down -11.87% year-over-year. In the year 2025, Precision BioSciences had annual revenue of $34.26M, down -50.12%.
Revenue (ttm)
$45.07M
Revenue Growth
-11.87%
P/S Ratio
4.14
Revenue / Employee
$662,838
Employees
68
Market Cap
186.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 34.26M | -34.43M | -50.12% |
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
| Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
| Dec 31, 2017 | 6.48M | -531.00K | -7.57% |
| Dec 31, 2016 | 7.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 151.12M |
| Arcturus Therapeutics Holdings | 54.71M |
| Innate Pharma | 10.57M |
| Milestone Pharmaceuticals | 1.78M |
| Cartesian Therapeutics | 1.78M |
DTIL News
- 3 days ago - Precision BioSciences Transcript: AGM 2026 - Transcripts
- 3 days ago - Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 - Business Wire
- 6 days ago - Precision BioSciences announces results from low-dose cohort of ECUR-506 - TheFly
- 10 days ago - Precision BioSciences presents new preclinical data on Pbgene-DMD program - TheFly
- 10 days ago - Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
- 19 days ago - Precision BioSciences Earnings release: Q1 2026 - Filings
- 19 days ago - Precision BioSciences Quarterly report: Q1 2026 - Filings
- 19 days ago - Precision BioSciences sees cash runway through 2028 - TheFly